Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders - Seite 2

Dr. Dugel commented further, “The contributions of Dr. Waheed, Dr. Kaiser and Dr. Heier, combined with the additions of Dr. Gibson, as Vice President, Medical Collaborations, and Dr. Saroj as Development Strategy Consultant, will bolster the effective execution of the AXPAXLI clinical program for retinal disease. In addition, I believe our strengthened clinical team also puts Ocular in an excellent position to accelerate expansion into retinal indications beyond wet AMD, including diabetic retinopathy.”

Dr. Waheed said, “I am honored to be part of the Ocular Therapeutix team. My experience as a retinal surgeon, combined with my background in scientific and clinical research and direct patient care inspired my desire to bring innovative new therapies to people with retinal diseases. Getting involved in the industry and becoming a CMO has allowed me to take a leadership role in this work. Joining Ocular allows me to build on my prior experiences as a CMO and work on a drug candidate that has the potential to dramatically change the treatment paradigm for retinal diseases and significantly improve patient compliance. I believe AXPAXLI has the potential to provide a durable reduction in disease burden to patients with wet AMD and diabetic retinopathy and I look forward to working with Pravin and my colleagues to advance the clinical development of the product candidate.”

Dr. Kaiser commented, “Over the course of my career as a retinal surgeon, I have had the privilege of working on several approved products for wet AMD and other ophthalmic indications. I joined Ocular because I believed that AXPAXLI could be a ‘game-changer’ in the care of retinal disease. I am enthusiastic to apply the breadth of my experience to Ocular in my role as CDO. As we work together to advance the Phase 3 AXPAXLI program, I look forward to welcoming Dr. Waheed and continuing my work with the outstanding team at Ocular.”

Dr. Gibson commented, “There is an unmet need for clinical trial options available to newly diagnosed wet AMD patients who may be earlier in their disease course. I am excited to work with Ocular to advance the development of AXPAXLI and have the unique opportunity to bring a long-awaited clinical trial option to newly diagnosed patients.” Dr. Saroj noted further, “Bringing excellence in clinical development to the advancement of novel, FDA-approved products for ophthalmic diseases has been a highlight of my career. I look forward to working with this accomplished team towards the development of AXPAXLI.”